Tonix

TNXP NASDAQ
1.590
-0.060
-3.64%
盘后: 1.530 -0.06 -3.77% 19:41 06/14 EDT
开盘
1.650
昨收
1.650
最高
1.650
最低
1.560
成交量
7.04万
成交均量(3M)
68.44万
52周最高
48.90
52周最低
1.530
换手率
1.16%
市值
968.27万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Tonix TNXP股票价格,Tonix股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
展开 >

最近浏览

名称
价格
涨跌幅